Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V - Related Studies

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

This study has been completed.

Study NCT00097396. Last updated on September 25, 2008. Information provided by DynPort Vaccine Company LLC, A CSC Company

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Pneumonic Plague
		Preventive Therapy

2	Additional conditions recognized in this trial
		Plague

3	More general conditions related to this trial
		Bacterial Infections
		Enterobacteriaceae Infections
		Gram-Negative Bacterial Infections
		Yersinia Infections

4	Interventions listed in this trial
		rF1V vaccine

5	Sponsors listed in this trial
		DynPort Vaccine Company LLC, A CSC Company